Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Meisel, Andreas, Annane, Djillali, Vu, Tuan, Mantegazza, Renato, Katsuno, Masahisa, Aguzzi, Rasha, Frick, Glen, Gault, Laura, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134722/
https://www.ncbi.nlm.nih.gov/pubmed/37103755
http://dx.doi.org/10.1007/s00415-023-11699-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134722/
https://www.ncbi.nlm.nih.gov/pubmed/37103755
http://dx.doi.org/10.1007/s00415-023-11699-x

Ejemplares similares